Continuing therapeutic progress in lung cancer
Updated outcomes of KEYNOTE-010 of pembrolizumab for NSCLC
Genetic evolution of NSCLC
CheckMate 153 trial: how long should nivolumab be taken for?
What is durvalumab’s future as a treatment option in lung cancer?